Literature DB >> 29380178

β-Thalassemia intermedia: a comprehensive overview and novel approaches.

Chingiz Asadov1, Zohra Alimirzoeva2, Tahira Mammadova2, Gunay Aliyeva2, Shahla Gafarova2, Jeyhun Mammadov3.   

Abstract

β-Thalassemia intermedia is a clinical condition of intermediate gravity between β-thalassemia minor, the asymptomatic carrier, and β-thalassemia major, the transfusion-dependent severe anemia. It is characterized by a significant clinical polymorphism, which is attributable to its genetic heterogeneity. Ineffective erythropoiesis, chronic anemia, and iron overload contribute to the clinical complications of thalassemia intermedia through stepwise pathophysiological mechanisms. These complications, including splenomegaly, extramedullary erythropoiesis, iron accumulation, leg ulcers, thrombophilia, and bone abnormalities can be managed via fetal hemoglobin induction, occasional transfusions, chelation, and in some cases, stem cell transplantation. Given its clinical diversity, thalassemia intermedia patients require tailored approaches to therapy. Here we present an overview and novel approaches to the genetic basis, pathophysiological mechanisms, clinical complications, and optimal management of thalassemia intermedia.

Entities:  

Keywords:  Complications; Non-transfusion-dependent thalassemia; Novel treatment; Transfusion; β-Thalassemia intermedia

Mesh:

Substances:

Year:  2018        PMID: 29380178     DOI: 10.1007/s12185-018-2411-9

Source DB:  PubMed          Journal:  Int J Hematol        ISSN: 0925-5710            Impact factor:   2.490


  147 in total

1.  Prevalence of fractures among the Thalassemia syndromes in North America.

Authors:  M G Vogiatzi; E A Macklin; E B Fung; E Vichinsky; N Olivieri; J Kwiatkowski; A Cohen; E Neufeld; P J Giardina
Journal:  Bone       Date:  2005-11-17       Impact factor: 4.398

2.  Prospects for a hepcidin mimic to treat β-thalassemia and hemochromatosis.

Authors:  Nermi L Parrow; Sara Gardenghi; Stefano Rivella
Journal:  Expert Rev Hematol       Date:  2011-06       Impact factor: 2.929

3.  Pregnancy in β-thalassemia intermedia at two tertiary care centers in Lebanon and Italy: A follow-up report on fetal and maternal outcomes.

Authors:  Joseph E Roumi; Hassan M Moukhadder; Giovanna Graziadei; Martina Pennisi; Maria Domenica Cappellini; Ali T Taher
Journal:  Am J Hematol       Date:  2017-03-04       Impact factor: 10.047

4.  Increased circulating platelet aggregates in thalassaemia.

Authors:  P Winichagoon; S Fucharoen; P Wasi
Journal:  Southeast Asian J Trop Med Public Health       Date:  1981-12       Impact factor: 0.267

5.  Frequency and specificity of red cell antibodies in thalassemia patients in Albania.

Authors:  I Seferi; M Xhetani; M Face; G Burazeri; E Nastas; G Vyshka
Journal:  Int J Lab Hematol       Date:  2015-04-11       Impact factor: 2.877

6.  Bone mineral metabolism in adults with beta-thalassaemia major and intermedia.

Authors:  R Dresner Pollack; E Rachmilewitz; A Blumenfeld; M Idelson; A W Goldfarb
Journal:  Br J Haematol       Date:  2000-12       Impact factor: 6.998

7.  PADGEM/GMP-140 expression on platelet membranes from homozygous beta thalassaemic patients.

Authors:  D Del Principe; A Menichelli; S Di Giulio; W De Matteis; P Cianciulli; G Papa
Journal:  Br J Haematol       Date:  1993-05       Impact factor: 6.998

8.  Treatment of 100 chronic thalassemic leg wounds by plasma-rich platelets.

Authors:  Hojjat Afradi; Yassaman Saghaei; Zohre A Kachoei; Vahid Babaei; Shahram Teimourian
Journal:  Int J Dermatol       Date:  2016-09-26       Impact factor: 2.736

Review 9.  Guidelines for diagnosis and management of Beta-thalassemia intermedia.

Authors:  Mehran Karimi; Nader Cohan; Vincenzo De Sanctis; Naji S Mallat; Ali Taher
Journal:  Pediatr Hematol Oncol       Date:  2014-10       Impact factor: 1.969

10.  BCL11A enhancer dissection by Cas9-mediated in situ saturating mutagenesis.

Authors:  Matthew C Canver; Elenoe C Smith; Falak Sher; Luca Pinello; Neville E Sanjana; Ophir Shalem; Diane D Chen; Patrick G Schupp; Divya S Vinjamur; Sara P Garcia; Sidinh Luc; Ryo Kurita; Yukio Nakamura; Yuko Fujiwara; Takahiro Maeda; Guo-Cheng Yuan; Feng Zhang; Stuart H Orkin; Daniel E Bauer
Journal:  Nature       Date:  2015-09-16       Impact factor: 49.962

View more
  19 in total

1.  Analysis of determinant factors of liver fibrosis progression in ex-thalassemic patients.

Authors:  Tahereh Rostami; Seyed Mostafa Monzavi; Hossein Poustchi; Ali Reza Khoshdel; Maryam Behfar; Amir Ali Hamidieh
Journal:  Int J Hematol       Date:  2020-10-08       Impact factor: 2.490

2.  Subclinical Left Ventricular Dysfunction in Children and Adolescence With Thalassemia Intermedia.

Authors:  Roya Isa Tafreshi; Mohammad Radgoodarzi; Kadijeh Arjmandi Rafsanjani; Fahimeh Soheilipour
Journal:  Front Pediatr       Date:  2022-06-17       Impact factor: 3.569

Review 3.  Genetic Manipulation Strategies for β-Thalassemia: A Review.

Authors:  Nur Atikah Zakaria; Rosnah Bahar; Wan Zaidah Abdullah; Abdul Aziz Mohamed Yusoff; Shaharum Shamsuddin; Ridhwan Abdul Wahab; Muhammad Farid Johan
Journal:  Front Pediatr       Date:  2022-06-15       Impact factor: 3.569

4.  Development of a double shmiR lentivirus effectively targeting both BCL11A and ZNF410 for enhanced induction of fetal hemoglobin to treat β-hemoglobinopathies.

Authors:  Boya Liu; Christian Brendel; Divya S Vinjamur; Yu Zhou; Chad Harris; Meaghan McGuinness; John P Manis; Daniel E Bauer; Haiming Xu; David A Williams
Journal:  Mol Ther       Date:  2022-05-06       Impact factor: 12.910

Review 5.  Stress erythropoiesis: definitions and models for its study.

Authors:  Robert F Paulson; Sneha Hariharan; Jane A Little
Journal:  Exp Hematol       Date:  2020-08-02       Impact factor: 3.084

6.  Long-term safety and efficacy of hydroxyurea in patients with non-transfusion-dependent β-thalassemia: a comprehensive single-center experience.

Authors:  Mehran Karimi; Tahereh Zarei; Ardeshir Bahmanimehr; Azam Aramesh; Saeed Daryanoush; Sezaneh Haghpanah
Journal:  Ann Hematol       Date:  2021-08-12       Impact factor: 3.673

7.  Quantification of liver iron overload disease with laser ablation inductively coupled plasma mass spectrometry.

Authors:  Philipp Kim; Sabine Weiskirchen; Ricarda Uerlings; Astrid Kueppers; Florian Stellmacher; André Viveiros; Heinz Zoller; Ralf Weiskirchen
Journal:  BMC Med Imaging       Date:  2018-12-04       Impact factor: 1.930

8.  Relationship between liver iron concentration determined by R2-MRI, serum ferritin, and liver enzymes in patients with thalassemia intermedia.

Authors:  Hayder Al-Momen; Shaymaa Kadhim Jasim; Qays Ahmed Hassan; Hayder Hussein Ali
Journal:  Blood Res       Date:  2018-12-17

9.  Hb Knossos (HBB: c.82G > T), β-globin CD 5 (-CT) (HBB: c.17_18delCT) and δ-globin CD 59 (-a) (HBD: c.179delA) mutations in a Syrian patient with β-thalassemia intermedia.

Authors:  Faten Moassas; Mohamad Sayah Nweder; Hossam Murad
Journal:  BMC Pediatr       Date:  2019-02-18       Impact factor: 2.125

10.  Gastrointestinal iron excretion and reversal of iron excess in a mouse model of inherited iron excess.

Authors:  Courtney J Mercadante; Milankumar Prajapati; Jignesh H Parmar; Heather L Conboy; Miriam E Dash; Michael A Pettiglio; Carolina Herrera; Julia T Bu; Edward G Stopa; Pedro Mendes; Thomas B Bartnikas
Journal:  Haematologica       Date:  2018-11-08       Impact factor: 9.941

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.